SEC Company Response from GENEREX BIOTECHNOLOGY CORP (CIK 0001059784) — Sep 11, 2020
GENEREX BIOTECHNOLOGY CORP (CIK 0001059784)
Date: Sept. 11, 2020 · CIK: 0001059784 · Accession: 0001607062-20-000265
AI Filing Summary & Sentiment
File numbers found in text: 333-248205
Letter
GENEROX BIOTECHNOLOGY CORPORATION
USA Today Way
Miramar, FL 33025
September 11, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Attention: Ada D. Sarmento
Joe McCann
Re: Generex Biotechnology Corporation
Registration Statement on Form S-1, as amended
File No. 333-248205
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Generex Biotechnology Corporation. (the “Company”) respectfully requests that the effective date of the registration statement referred to above (the “Registration Statement”) be accelerated so that it will become effective at 4:00 p.m., Eastern Time, on Monday, September 14, 2020, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Carmel, Milazzo & Feil LLP by calling Jeffrey Wofford at (646) 876-0618. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Carmel, Milazzo & Feil LLP, Attention: Jeffrey Wofford, by facsimile to (646) 838-1314 or email at jwofford@cmfllp.com.
If you have any questions regarding this request, please contact Jeffrey Wofford of Carmel, Milazzo & Feil LLP at (646) 876-0618.
Very Truly Yours,
By:
/s/
Joseph Moscato
Show Raw Text
CORRESP
1
filename1.htm
GENEROX
BIOTECHNOLOGY CORPORATION
10102
USA Today Way
Miramar,
FL 33025
September
11, 2020
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attention: Ada
D. Sarmento
Joe
McCann
Re: Generex
Biotechnology Corporation
Registration
Statement on Form S-1, as amended
File
No. 333-248205
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”),
Generex Biotechnology Corporation. (the “Company”) respectfully requests that the effective date of the registration
statement referred to above (the “Registration Statement”) be accelerated so that it will become effective
at 4:00 p.m., Eastern Time, on Monday, September 14, 2020, or as soon thereafter as possible. In making this acceleration request,
the Company acknowledges that it is aware of its responsibilities under the Act.
Once
the Registration Statement is effective, please orally confirm the event with our counsel, Carmel, Milazzo & Feil LLP by calling
Jeffrey Wofford at (646) 876-0618. We also respectfully request that a copy of the written order from the Securities and Exchange
Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to
our counsel, Carmel, Milazzo & Feil LLP, Attention: Jeffrey Wofford, by facsimile to (646) 838-1314 or email at jwofford@cmfllp.com.
If
you have any questions regarding this request, please contact Jeffrey Wofford of Carmel, Milazzo & Feil LLP at (646) 876-0618.
Very Truly Yours,
By:
/s/
Joseph Moscato
Name: Joseph Moscato
Title: Chief Executive Officer
cc: Jeffrey
Wofford, Carmel, Milazzo & Feil LLP